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LIST OF ABBREVIATIONS 
 
Cy3g: Cyanidin-3-glucoside 
PGC-1α: Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha 
SIRT1: Sirtuin 1 
MMP: Mitochondrial membrane potential 
ATP: Adenosine triphosphate 
TFAM: Mitochondrial transcription factor A 
NRF1: Nuclear respiratory factor-1 
ROS : reactive oxygen species  
CPT-1β: Carnitine palmitoyltransferase 1 beta 
CDE: choline-deficient, ethionine-supplemented diet 
PFK-1: Phosphofructokinase 1 
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ABSTRACT 
Mitochondrial dysfunction has been identified as one of the 
primary factors contributing to liver diseases. Pathways that 
control mitochondrial biogenesis are potential therapeutic targets 
for the amelioration of hepatocyte dysfunction and liver disease. 
Research on natural pharmacological agents that ameliorate liver 
diseases has intensified over the last two decades. Cyanidin-3-
glucoside (Cy3g), a dietary flavonoid compound extracted from a 
wide variety of fruits and vegetables, reportedly has several 
beneficial health effects. In this study, we used an adult human 
hepatoma cell line (HuH7) to investigate the effects of the Cy3g 
polyphenolic compound on mitochondrial function and 
biogenesis in vitro. An increase in intracellular mitochondrial 
reductase levels was observed after treatment with Cy3g, but 
cytotoxicity was not induced. In addition, mitochondrial 
membrane potential and ATP production were increased 
following Cy3g treatment. Cy3g treatment also resulted in a dose- 
and time-dependent upregulation of the gene expression of 
peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α), a transcription factor considered a master 
regulator of mitochondrial biogenesis and metabolism. 
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Additionally, the expression of sirtuin 1 (SIRT1), which plays a 
key role in deacetylating PGC-1α, was also increased in a dose- 
and time-dependent manner. Cy3g treatment also increased the 
expression of downstream PGC-1α genes, nuclear respiratory 
factor 1 and mitochondrial transcription factor A (TFAM). Our 
results suggest that Cy3g has potential as a hepatoprotective 
therapeutic agent that enhances mitochondrial function and 
biogenesis in hepatocytes. 	 	
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INTRODUCTION 
- Mitochondria role in health and diseases  
Mitochondria are the main organelles that maintain energy 
production, control metabolism and regulate stress within cells 
(Wallace 2005; Nunnari and Suomalainen 2012). Mitochondrial 
health is an important parameter of overall cell health. 
Mitochondrial dysfunction has been found to be a key factor 
leading to the development of a variety of diseases, such as 
neurodegenerative disorders (Johri and Beal 2012), endocrine 
dysfunction (Chow et al. 2016), and several metabolic disorders, 
such as insulin resistance (Petersen et al. 2003; Morino et 
al. 2006), as well as hepatic and cardiovascular diseases 
(Gustafsson and Gottlieb 2007; Nassir and Ibdah 2014). 
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- Mitochondrial dysfunction and liver diseases 
Many studies have reported the direct relationship between 
mitochondrial dysfunction and liver diseases (Pessayre et al. 2002; 
Begriche et al. 2006; Rector et al. 2010; Nassir and Ibdah 2014). 
Disrupted hepatocyte metabolism results in lipid retention in 
hepatocytes(Fig.1). This retention has been attributed to failed long 
chain fatty acid catabolism via hepatic mitochondrial β-oxidation 
(Fabbrini et al. 2010). 
 
Fig.1  Mitochondrial role in liver disease; hepatic mitochondrial 
dysfunction leads to elevated oxidative stress and eventual progression of 
liver disease. 
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-  PGC-1α  as a master of mitochondrial biogenesis 
In Homo sapiens and eukaryotic animals, cell mitochondrial 
biogenesis and metabolic control are orchestrated by several 
factors. Among these, one important factor has emerged in the past 
decade, called Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α). PGC-1α controls mitochondrial 
biogenesis via the activation of several downstream genes, such as 
mitochondrial transcription factor A (TFAM), which is triggered by 
nuclear respiratory factor-1/-2 (NRF1/2) (Finck and Kelly 2006). 
Fasting or hypothermia, which help the cell adapt to nutritional 
status, can trigger PGC-1α. Disruption of this mechanism has been 
associated with the development of mitochondrial dysfunction-
related diseases (Vega et al. 2000; Scarpulla 2011). Sirtuin 1 
(SIRT1), a homolog of SIRT2, was observed to cooperate with PGC-
1α to regulate hepatocyte gluconeogenesis and glycolysis-related 
genetic controlling processes (Rodgers et al. 2005). A study 
reported that PGC-1α impairment in the CDE fed rodent liver 
	 9	
results in impaired mitochondrial biogenesis and lipid metabolism, 
eventually exacerbating fatty liver diseases  (Aharoni-Simon et 
al. 2011)(Fig.2). 
 
 
 
 
 
 
Fig.2  PGC-1α in mitochondria; Impairment of  the master of 
mitochondrial biogenesis PGC-1α leads to less mitochondrial biogenesis, 
gluconeogenesis and β-oxidation of free fatty acids in liver. 
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- Therapeutic potential of Anthocyanins  
The search has intensified for natural product treatments that can 
replace or synergize with current pharmaceutical products and 
minimize pharmaceutical side effects and financial burdens 
(Bagchi et al. 2015). Anthocyanidins, which are anthocyanins 
bound with aglycone are a group of flavonoids. Anthocyanins are 
pigments that exist in many fruits and vegetables and result in red, 
blue and violet colours. Recently, anthocyanins have gained 
attention for their protective and health benefits. Anthocyanins 
bioavailability was investigated in human and animals, using 
extracts as anthocyanin sources , anthocyanins were rapidly 
absorbed in both animal models  (Fornasaro et al.2016; Kalt et al., 
2008; Ali et al., 2005; de Boer et al.,2005) and humans  (Bub et al., 
2001; Cao & Prior, 1999; Matsumoto et al., 2001; Mazza et 
al.,2002; Prior & Wu, 2006). Cyanidin-3-glucoside (Cy3g), a 
water-soluble anthocyanin dietary flavonoid compound extracted 
from a wide variety of fruits and vegetables, has been reported to 
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have multiple beneficial effects(Fig.3). A clinical study found that 
the intake of this compound minimizes cardiovascular risk 
(Cassidy et al. 2013). 
 
 
Fig.3  The chemical structure for Cyanidin-3-glucoside 
 
-  Mitochondria as a potential target of Anthocyanin 
 Cy3g resulted in increased brown adipose tissue mitochondrial 
function (You et al. 2017). In addition, treating different rodents 
models with Cy3g resulted in hepatocyte protection and prevented 
obesity and insulin resistance (Jiang et al. 2014, Wei et al. 2011). 
Our previous reports indicate that Cy3g benefits skeletal muscle 
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aerobic capacity and enhances adipose tissue metabolism 
(Matsukawa et al. 2015, 2017). 
The HuH7 cell line is a well-differentiated, established adult 
hepatoma cell line that provides a good in vitro system to test the 
effects of natural compounds on hepatocyte metabolism (Chavez-
Tapia et al. 2012; Krelle et al. 2013). In this study, we investigated 
the effects of Cy3g on mitochondrial function and biogenesis using 
the HuH7 cell line as a hepatocyte model. 
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MATERIALS AND METHODS 
- Chemicals  
Cy3g (98% HPLC Purity) was purchased from Tokiwa 
Phytochemical Co., Ltd. Japan. The well-differentiated human 
hepatocellular carcinoma HuH7 cell line was purchased from the 
National Institutes of Biomedical Innovation Health and 
Nutrition JCRB Bank (JCRB No. JCRB0403, Tokyo, Japan). The 
cell culture medium was Dulbecco’s modified Eagle’s medium 
(DMEM) containing low glucose (Sigma, Tokyo, Japan). 
Penicillin/streptomycin and trypsin/EDTA were obtained from 
Lonza (Tokyo, Japan). Fetal bovine serum (FBS) and Hanks’ 
balanced salt solution (HBSS) were purchased from Gibco (USA). 
Sodium dodecyl sulfate (SDS) was purchased from Wako (Tokyo, 
Japan). 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) and Triton X-100 were purchased from Sigma (MO, 
USA). MTT was purchased from Dojindo Co., Ltd. (Kumamoto, 
Japan). Guava ViaCount and Check Kit reagents were purchased 
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from Guava Technologies Co., Ltd. USA. Rhodamine 123 was 
purchased from Wako. 
- Cell culture 
Cells were cultured in 75-cm2 culture flasks with low glucose 
DMEM supplemented with 10% heat-inactivated FBS and  1% 
penicillin (5000 µg/ml)–streptomycin (5000 IU/ml) at 37 °C in 
an incubator with 5% CO2. The growth medium was changed 
every other day, and the experiments were completed with cells 
between passages 3–7 and at no more than 70–80% confluence. 
Passaging was performed with trypsin/EDTA. 
- MTT assay 
Cells were seeded at a concentration of 3 × 103 cells per well in 
DMEM 10% FBS culture medium in 96-well plates and cultured 
for 24 h. Then, the cells were treated with different concentrations 
of Cy3g compound for different time intervals. Under dark 
settings, the cells were then washed with phosphate-buffered 
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saline (PBS) and incubated with MTT reagent (5 g/l) for 3 h. MTT 
formazan crystals were then dissolved in 10% SDS and kept 
overnight at room temperature. Optical density was measured 
using a Powerscan HT plate reader (Dainippon Sumitomo 
Pharma Co., Ltd., Japan). The results were normalized to those of 
the control group. All experiments were performed in triplicate. 
- Guava cell count 
The Guava ViaCount assay , which is a DNA-binding fluorescense 
dye, was conducted on untreated and treated suspension cultures 
according to the manufacturer’s protocol (Cat. No. 4000-0040). 
Guava ViaCount staining reagent (380 µl) was added and mixed 
with 20 µL of cell suspension in a 1.5-mL tube. Then, the 
suspension was kept in the dark for 5 min at room temperature. A 
Guava PCA machine (Guava Technologies) was used to analyze 
the samples. Readings were acquired using Cytosoft software 
(version 2.1.2). Machine performance was assessed using the 
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Guava check application with a Guava Check kit (Cat. No. 4500-
0020). 
- ATP assay 
Cellno ATP assay reagent (Toyo Inc., Tokyo, Japan) was used in 
accordance with the manufacturer’s protocol to measure 
intracellular ATP levels. HuH7 cells were treated with different 
concentrations of Cy3g compound for various times and then 
incubated with ATP assay reagents for 15 min at room 
temperature. A Powerscan HT plate reader (Dainippon Sumitomo 
Pharma Co., Ltd.) was used to detect luminescence. 
-Mitochondrial membrane potential (MMP) 
MMP was measured using rhodamine 123 fluorescent dye. Cells 
were treated with Cy3g at various concentrations and time 
intervals. Then, the cells were incubated with the rhodamine 123 
dye (10 µg/ml) in 10 mM HEPES-HBSS buffer (pH 7.4) for 
20 min at 37 °C. After lysing HuH7 cells using 1% Triton X-100 
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(Sigma-Aldrich™ Co., Ltd., USA), a Powerscan HT plate reader 
(Dainippon Sumitomo Pharma Co., Ltd., Japan) was used to 
quantify rhodamine 123 fluorescence intensity (excitation 
485 nm/emission 528 nm). 
- Real-time PCR analysis 
HuH7 cells were plated in a 60-mm cell culture dish. After 24 h, 
the cells were incubated with different Cy3g concentrations for 
different times (1, 3, 6, and 24 h). Total RNA from HuH7 cells was 
isolated using Macherey–Nagel’s RNA extraction kit (Macherey–
Nagel GmbH & Co. KG, Germany). The extraction process was 
executed according to the manufacturer’s protocol. The quantity 
of RNA was evaluated using a NanoDrop 2000 
Spectrophotometer (Thermo Scientific™, Inc.,	 Wilmington, DE, 
USA). Reverse transcription (RT) reactions were carried out with 
the SuperScript III RT kit (Invitrogen Co., Ltd., Carlsbad, CA, 
USA). The following primer sets and TaqMan probes for 
experimental genes were purchased from Applied Biosystems 
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(CA, USA): GADPH (Hs02786624_g1), PGC-1α 
(Hs01016719_m1), TFAM (Hs00273327_s1), NRF1 
(Hs00602161_m1), SIRT1 (Hs01009006_m1), CPT-1β 
(Hs03046298_s1) and PFK1 (Hs01075411_m1). The mRNA 
expression level of each gene was normalized using GADPH as an 
internal control.	Fold changes were calculated using 2-ddCt. 
- Statistical analysis 
All experiments were repeated three times. The experimental data 
are presented as the mean ± standard deviation. When two values 
were compared (control vs. treatment), statistical significance was 
assessed by Student’s unpaired t-test using Microsoft Excel (iOS 
Version 2011; Microsoft Inc., USA). P≤ 0.05 was considered 
statistically significant. 
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RESULTS 
- Cy3g increased mitochondrial reduction activity  
The MTT (3-(4,5-dimethylthiazol-2-yl)-diphenyl tetrazolium 
bromide) assay was used to examine the mitochondrial reduction 
of the Cy3g compound on the HuH7 hepatoma cell line at 
different times and concentrations. The study revealed that Cy3g 
did not reduce cell viability. The MTT assay is a classic method for 
evaluating cell mitochondrial function via intracellular 
mitochondrial reduction of MTT to formazan (Brand and 
Nicholls 2011). Compared with the control, the increased 
absorbance induced by 25 and 50 µM Cy3g indicated that cell 
mitochondrial reduction activity was upregulated dose-
dependently by 130 and 139%, respectively, at 24 h. In addition, 
absorbance was increased to 112 and 125% after treatment with 25 
and 50 µM Cy3g, respectively, at 48 h (Fig. 4). Guava cell assay 
was used to assess cell proliferation, treatment with Cy3g did not 
decrease or increase cell proliferation (Fig. 5). 
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 Fig. 4 Effect of Cy3g treatment on cell proliferation; Cell 
proliferation was measured using MTT assays, and the HuH7 
adult human hepatoma cell line was cultured at 3 × 103 cell per 
well with or without (control) different concentrations of Cy3g (1, 
5, 10, 25 or 50 µM) for different time periods (24 or 48 hr). Values 
represent the means of three independent experiments ± 
standard deviation. The bars with asterisk marks are significantly 
different from the control at P≤0.05 (*) or P≤0.01 (**) 
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Fig. 5 Cytotoxicity of Cy3g; Guava count assays were used to 
detect the number of adult human hepatoma HuH7 cells cultured 
with or without (control) 50 µM Cy3g for 24 hr. Values represent 
the means of three independent experiments ± standard 
deviation. The bar with NS mark is non significantly different 
from the control. 
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- Cy3g increased intracellular ATP production in HuH7 
cells 
The compound had no cytotoxic effect on HuH7 cells (MTT assay 
result). Then, Cellno ATP assay was used to determine the effects 
of Cy3g on the intracellular ATP levels in HuH7 cells. 
Luminescence readings indicated that compared with the control 
treatment, Cy3g treatment significantly increased the intracellular 
ATP level to 109% at the 25 µM concentration and to 117% at the 
50 µM concentration (Fig. 6).		
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Fig. 6  Effect of Cy3g treatment on ATP production; measurement 
of intracellular ATP in the HuH7 adult human hepatoma cell line, 
cultured without Cy3g (control) or with different concentrations 
of Cy3g (5, 25 or 50 µM) for different time periods (24 or 48 hr). 
Values represent the means of three independent experiments ± 
standard deviation. The bars with asterisk marks are significantly 
different from the control at P≤0.05 (*) or P≤0.01 (**). 
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- Cy3g increased the MMP 
 
The majority of ATP production occurs within the mitochondria 
via oxidative phosphorylation: the mitochondrial electron 
transport chain creates an electrochemical gradient that induces 
ATP synthesis and generates the MMP, which is a good indicator 
of mitochondrial health (Sakamuru et al. 2016). Rhodamine 123 is 
a cationic, membrane-permeable fluorescent staining dye that is 
used to measure the inner MMP, which is a sensitive indicator of 
mitochondrial health (Sakamuru et al. 2016). In our experiment, 
compared with those of control-treated cells after 24 h, 
fluorescence readings significantly increased to 108 and 117% in 
25 and 50 µM Cy3g-treated cells, respectively. After 48 h of 
treatment, fluorescence was increased 112% in cells treated with 
50 µM Cy3g (Fig. 7), indicating that Cy3g increased the 
mitochondrial transmembrane potential in HuH7 cells. 
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Fig. 7  Effect of Cy3g treatment on mitochondrial MMP; measurement of 
mitochondrial depolarization activity in the HuH7 adult human hepatoma 
cell line, cultured without Cy3g (control) or with different concentrations 
of Cy3g (5, 25 or 50 µM) for different time periods (24 or 48 hr). Values 
represent the means of three independent experiments ± standard 
deviation. The bars with asterisk marks are significantly different from 
the control at P≤0.05 (*) or P≤0.01 (**). 
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- Cy3g treatment dose- and time-dependently increased 
PGC-1α and SIRT1 gene expression levels 
The polyphenol Cy3g dose-dependently upregulated PGC-1α and 
SIRT1 gene expression, and these genes have been reported to 
play a key role in the control of metabolic adaption and 
mitochondrial biogenesis (Finck and Kelly 2006; Ventura-Clapier 
et al. 2008; Cantó and Auwerx 2009). Cy3g significantly 
upregulated PGC-1α gene expression in a dose-dependent 
manner, from a 1.5-fold change at the 25 µM dose to a twofold 
change at the 50 µM dose (*P ≤ 0.01) (Fig. 8a). Regarding SIRT1 
gene expression, 25 and 50 µM Cy3g increased the level 1.2- to 
1.7-fold, respectively (Fig. 8b). 
 
 
 
	 27	
 
Fig. 8 PGC-1α and SIRT1 upregulation by cy3g treatment; the effects of 
Cy3g on HuH7 cell PGC-1α (Fig. 8a) and SIRT1 (Fig. 8b) mRNA 
expression after treatment with different concentrations of Cy3g (25 µM 
and 50 µM) for 24 hrs. The gene expression level was normalized to the 
GADPH expression level. Values are expressed as the means ± standard 
deviation of triplicate experiments. *P≤0.05 and **P≤0.01 indicate that 
the mean value is significantly different from that of the control group. 
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Cy3g resulted in a time-dependent increase in PGC-1α and SIRT1 gene 
expression levels. The 25 µM concentration was selected to evaluate 
PGC-1α and SIRT1 levels at different time intervals (1, 3, 6, and 24 h). 
PGC-1α and SIRT1 gene expression levels peaked at 3 h in treated cells 
compared with those in control cells, with significant 2.0-fold increases 
(*P ≤ 0.01). Cy3g treatment also significantly increased PGC-1α and 
SIRT1 gene expressions after 24 hrs. , with fold changes of 1.50 and 
1.27, respectively (P ≤ 0.01) (Fig. 9). 
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  Fig. 9 Cy3g effect on PGC-1α and SIRT1 mRNA expression with 
time; effects of Cy3g on HuH7 cell PGC-1α and SIRT1 mRNA 
expression levels were measured at different time intervals (1, 3, 6 
and 24 h after treatment with 25 µM Cy3g), and the gene 
expression level was normalized to the GADPH expression level. 
Values are expressed as the mean ± standard deviation of 
triplicate experiments. *P ≤ 0.05 and **P ≤ 0.01 indicate that the 
mean value is significantly different from that of the control 
group. 
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- The effect of Cy3g on PGC-1α and SIRT1 downstream 
genes 
Treatment with Cy3g (25 µM) for 24 hrs significantly increased the 
expression of PGC-1α-coactivated downstream genes, such as NRF1, 
approximately 2.5-fold. Cy3g increased the TFAM level by 
approximately 1.3-fold. TFAM is a nuclear-encoded transcription 
factor that plays a key role in mitochondrial DNA replication and 
transcription and is regulated by NRF1 (Finck and Kelly 2006). In 
addition, Cy3g increased CPT-1β levels approximately 2.3-fold (Fig. 
10). CPT-1β is located within the mitochondrial outer membrane and is 
considered the rate-limiting enzyme of mitochondrial β-oxidation, as it 
controls mitochondrial uptake of long chain acyl-CoA fatty acids. 
Increased PGC-1α levels have been found to increase the CPT-1β level, 
thus increasing the fatty acid oxidative capacity of the mitochondria 
(Song et al. 2010; Nikolić et al. 2012). Furthermore, Cy3g treatment 
increased phosphofructokinase 1 (PFK-1) gene expression 
approximately 1.7-fold. PFK-1 is an important regulator of glycolysis 
(Han et al. 2016) (Fig. 10). 
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Fig. 10  The effects of Cy3g treatment on PGC-1α downstream gene 
mRNA expression in HuH7 cells; The effects of Cy3g on HuH7 cell 
PGC-1α downstream gene mRNA expression levels were measured at 
24 hr. After treatment with 25 µM Cy3g, the gene expression levels 
(TFAM, NRF1, CPT-1β, PFK-1) were normalized to the GADPH 
expression level. Values are expressed as the means ± standard 
deviation of triplicate experiments. *P≤0.05, **P≤0.01 indicates that 
the mean value is significantly different from that of the control group. 
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DISCUSSION 
 
The search for natural herbal compounds and extracts that treat 
or prevent disease has intensified during the last decade. Several 
studies have reported the beneficial effects of a variety of natural 
compounds, such as resveratrol, quercetin and catechin on health 
(Watson et al. 2013). 
Among anthocyanin compounds, Cy3g, a phenol pigment that 
belongs to the flavonoid family, has been shown to have beneficial 
effects in several in vitro and in vivo clinical trials (Watson et 
al. 2013). Clinical trials had found that Cy3g’s bioavailability is 
higher than previously perceived, and their metabolites are 
detected in the blood within 48 h after oral intake(Czank et al. 
2013). Previously, we reported that Cy3g enhances skeletal 
muscle mitochondrial biogenesis by upregulating PGC-1α levels 
via the elevation of cyclic AMP levels (Matsukawa et al. 2017). 
PGC-1α is reportedly an essential factor for upregulating hepatic 
metabolism and is key for overall liver metabolism (Leone et 
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al. 2005; Finck and Kelly 2006). This study examined the effects 
of Cy3g on mitochondrial function and biogenesis in hepatic cells 
(HuH7) and elucidated the underlying mechanism. In this study, 
we found that Cy3g induced PGC-1α activity. This induction of 
PGC-1α gene expression was associated with a similar tendency 
for increased SIRT1 gene expression. 
Increased expression of PGC-1α-coactivated downstream genes, 
such as nuclear respiratory factor-1 (NRF1), which encodes 
respiratory chain subunits and other proteins necessary for 
mitochondrial function, was observed (Finck and Kelly 2006). 
Moreover, Cy3g increased the gene expression of mitochondrial 
transcription factor A (TFAM), a nuclear-encoded transcription 
factor that plays a key role in mitochondrial DNA replication and 
transcription and is regulated by NRF1 (Finck and Kelly 2006). 
Cy3g also increased CPT-1β gene expression, which is located 
within the mitochondrial outer membrane and is considered the 
rate-limiting enzyme of mitochondrial β-oxidation as CPT-1β 
	 34	
controls the mitochondrial uptake of long chain acyl-CoA fatty 
acids. Moreover, increased PGC-1α levels have been found to 
increase the CPT-1 β level, thus increasing the fatty acid oxidative 
capacity of mitochondria (Song et al. 2010; Nikolić et al. 2012). 
Cy3g also increased PFK-1 gene expression, an important 
regulator of glycolysis (Han et al. 2016). Currently, lifestyle 
modification and caloric restriction are the only treatments for 
nonalcoholic fatty liver diseases (Nassir and Ibdah 2016). Some 
polyphenol compounds, such as resveratrol, have shown calorie 
restriction-mimicking effects in mammalian diseases and can 
ameliorate liver fat accumulation in high-fat diet mouse models, 
mostly due to the activation of metabolism-sensing signaling 
systems (Baur et al. 2006; Ajmo et al. 2008; Li et al. 2016). While 
several pathways control mitochondrial function, biogenesis and 
free fatty acid oxidation, a recently identified member of the 
Peroxisome proliferator-activated receptor gamma (PPAR-γ) 
coactivator family, PGC-1α, serves as a major regulator of the 
nuclear receptors that control metabolic pathways and is 
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expressed in tissues with high oxidative capacity such as muscle 
and liver tissues (Finck and Kelly 2006). Hepatocytes extracted 
from PGC-1α-deficient mice exhibit reduced mitochondrial 
respiration rates, indicating a reduced hepatic fatty acid oxidation 
capacity (Leone et al. 2005). SIRT1 coexists with the transcription 
factor PGC-1α and plays an important role in PGC-1α activation 
via deacetylation (Rodgers et al. 2005). SIRT1 and PGC-1α 
signaling is important in the protection of in vitro hepatocyte 
models against mitochondrial oxidative stress (Tan et al. 2015). 
Furthermore, pharmacological activation of SIRT1 by polyphenol 
in HepG2 protected against FAS induction and lipid accumulation 
(Hou et al. 2008). 
Several studies have revealed the crucial role of sirtuins generally 
and SIRT1 specifically in liver diseases (Nassir and Ibdah 2016; 
Ding et al. 2017). SIRT1, an NAD+-dependent protein 
deacetylase, is an important regulator of energy homeostasis, 
enhanced mitochondrial metabolism, antioxidative protection, 
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lipid catabolism and glucose homeostasis (Canto and 
Auwerx 2012). Both in vitro and in vivo models of SIRT1 
deficiency have shown a tendency for increased lipid 
accumulation in the liver and down regulation of de novo hepatic 
lipid synthesis transcription factors, such as sterol regulatory 
element binding protein-1c (SREBP-1c) and carbohydrate 
response element binding protein (ChREBP) (Purushotham et 
al. 2009; Wang et al. 2010). Previously, Guo et al. (2012) reported 
that Cy3g decreased lipid accumulation in hepatocytes. Jiang et 
al. (2014) demonstrated the beneficial effect of Cy3g in protecting 
primary mouse hepatocytes from hyperglycemia-induced 
mitochondrial depolarization, and preincubation with Cy3g 
improved cell survival and reduced reactive oxygen species (ROS) 
generation by modulating mitochondrial dysfunction. Pathways 
that control mitochondrial biogenesis have been studied 
extensively to identify future therapeutic approaches to treat the 
mitochondrial dysfunction that leads to various liver and 
metabolic diseases (Davinelli et al. 2013). 
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CONCLUSION 
Our experiments showed that in a human-derived hepatocyte 
model (HuH7 cells), Cy3g is a potent activator of the SIRT1 and 
PGC-1α signaling pathways, inducing mitochondrial biogenesis 
and function and triggering an increase in PGC-1α downstream 
genes, and these effects are dose- and time-dependent (Fig.11). 
Therefore, this compound should be considered a therapeutic or 
preventive approach for diseases caused by hepatic cell 
mitochondrial-dysfunction. ------------	
 ---Fig. 11  Graphical abstract 
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Limitations 
In regard to the limitations of this study; we understand that 
primary cultured hepatocyte might be the suitable cell line for the 
study of drug metabolism studies. However the access to the 
primary hepatocytes is restricted,  those cells usually show 
phenotypic instability and functional variation making their 
utility for routine testing complicated (Castell et al. 2006). Several 
liver-derived hepatocytes cell lines such as HuH7 or HepG2 have 
been developed for drug metabolism studies or drug toxicity 
screening. These hepatoma cell lines provide an accessible source, 
stable phenotype and longer lifespan. However, the majority of 
currently used hepatoma cell lines might not be as good as 
primary cultured hepatocytes, given that hepatoma cells contain a 
low level of drug-metabolising enzymes (Donato et al. 2013). For 
future studies of food or drug metabolism studies we suggest the 
use of new approaches with more metabolic competent cell lines 
such as immortalised hepatocytes or progenitor-induced 
hepatocytes. 
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